Aastrom Biosciences Inc., of Ann Arbor, Mich., said results from an open-label phase IIa study of ixmyelocel-T, its cell therapy for treating advanced heart failure due to ischemic dilated cardiomyopathy (DCM), were published in Circulation Research.